NBI-921352 is a blocker of sodium channel protein type 8 subunit alpha, which can be used in the study of neurological pathology in the treatment of epilepsy.

 

Brand: BCM

 

Signaling Pathways: Membrane transporter/Ion channel

 

Solubility: Soluble in DMSO ( Need ultrasonic ).

 

Isomeric SMILES: CC1=CC(=C(C=C1N(C)[C@H]2CCN(C2)CC3=CC=CC=C3)F)S(=O)(=O)NC4=CSC=N4  

 

InChIKey: UCSHINHOAVARGQ-SFHVURJKSA-N  

 

InChI: InChI=1S/C22H25FN4O2S2/c1-16-10-21(31(28,29)25-22-14-30-15-24-22)19(23)11-20(16)26(2)18-8-9-27(13-18)12-17-6-4-3-5-7-17/h3-7,10-11,14-15,18,25H,8-9,12-13H2,1-2H3/t18-/m0/s1

 

Attribute
[Chem Name]	4-[[(3S)-1-benzylpyrrolidin-3-yl]-methylamino]-2-fluoro-5-methyl-N-(1,3-thiazol-4-yl)benzenesulfonamide
[Synonym]	Zandatrigine; NBI-921352; XEN901; XEN 901; XEN-901
[CAS No.]	2154406-04-7
[Formula]	C22H25FN4O2S2
[Molecular]	460.59
[Form]	White to light yellow solid
[Storage]	Powder: -20°C for 3 years. In solvent: -80°C for 2 years

Goods Tag